---
title: "Amneal completes acquisition of Kashiv BioSciences"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295404706.md"
description: "Amneal Pharmaceuticals has completed its acquisition of Kashiv BioSciences, establishing a fully integrated biosimilars platform. This move adds end-to-end R&D, manufacturing, and commercialization capabilities to Amneal's Affordable Medicines business, positioning biosimilars as a key growth pillar. The company aims to capitalize on over $300 billion in projected global opportunities from biologic loss of exclusivity over the next decade, with integration efforts currently underway."
datetime: "2026-08-10T12:07:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295404706.md)
  - [en](https://longbridge.com/en/news/295404706.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295404706.md)
generator: "portal-rs"
---

# Amneal completes acquisition of Kashiv BioSciences

-   Amneal completed its acquisition of Kashiv BioSciences, adding end-to-end biosimilar R&D, manufacturing, and commercialization capabilities. \* The deal creates a fully integrated biosimilars platform, positioning biosimilars as a long-term growth pillar within Amneal’s Affordable Medicines business. \* The combined business targets an expected surge in biologic loss of exclusivity, citing more than $300 billion of projected global opportunities over the next decade. \* Integration work is underway, focused on combining development and manufacturing operations while advancing the biosimilar pipeline. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100800PRIMZONEFULLFEED9806496) on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [AMRX.US](https://longbridge.com/en/quote/AMRX.US.md)

## Related News & Research

- [AMRX: Q2 revenue and profit surged, outlook raised, and biosimilar expansion accelerates with Kashiv](https://longbridge.com/en/news/294381748.md)
- [Sell Alert: Nikita Shah Cashes Out $2.56M In Amneal Pharmaceuticals Stock](https://longbridge.com/en/news/295951572.md)
- [Endovia Health opens FDA INAD file for CannEpil veterinary program](https://longbridge.com/en/news/296915045.md)
- [Bio-Works wins SEK 2.8 million order from new US mRNA medicine developer](https://longbridge.com/en/news/296870494.md)
- [GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy](https://longbridge.com/en/news/296748151.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**